OBJECTIVETo explore the effectiveness of Longjintonglin capsule in treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

METHODSOne hundred and thirty-six patients accorded with the demands of chronic prostatitis type III of National Institute of Health (NIH), among them there were 84 cases of chronic prostatitis type IIIA and 52 cases of type IIIB. All of the patients accepted oral Longjintonglin capsule for 3 tablets, 3 times per day, for 3 months. NIH- chronic prostatitis symptom index (NIH-CPSI) and counting leukocytes in expressed prostatic secretions (EPS) were used as target to evaluate the effectiveness.

RESULTSOne hundred and thirty-one cases accomplished treatment, in which there were 81 cases of type IIIA, and 50 cases of type IIIB. Overall scores of NIH-CPSI before and after treatment were(24.8 +/- 5.6) and (13.3 +/- 6.8) points respectively, which dropped significantly (average 11.5 points), (P < 0.01). The symptom scores before and after treatment were (15.4 +/- 4.3) and (8.7 +/- 3.9) respectively, which also decreased significantly (average 6.7 points), (P <0.01). The scores for quality of life before and after treatment were (9.4 +/- 3.7) and (4.6 +/- 2.7) respectively, which dropped significant (average 4.8 points) (P < 0.01). The leukocytes counts before and after treatment in patients with CP/CPPs type IIIA were (21.7 +/- 14.5)/HP and (8.8 +/- 12.6)/HP, respectively. Twenty-four cases(18.3%) got cured, 41 cases (31.3%) notable effect, 40 cases (30.5%) some effect, 26 cases (19.8%) no effect, and total effective rate was 80.1%. No apparent side effect was observed in all patients accepted treatment, especially for their kidney and hepatic function.

CONCLUSIONLongjintonglin capsule was a safe and effective medicine in treatment of CP/CPPS without significant side effect.